Delving into the Latest Updates on Wuhan Renfulikang Pharmaceutical Co., Ltd. with Synapse

Overview

Tags

Other Diseases

Respiratory Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

No Data

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

autotaxin(Ectonucleotide pyrophosphatase/phosphodiesterase 2)	1

主要目的：评价盐酸卡利拉嗪胶囊相对于阿立哌唑片在精神分裂症成人患者中的疗效。次要目的：评价盐酸卡利拉嗪胶囊相对于阿立哌唑片在精神分裂症成人患者中的安全性和耐受性。探索性目的：探索受试者对于治疗体验的主观感受。

[Translation]

Primary objective: To evaluate the efficacy of cariprazine hydrochloride capsules compared with aripiprazole tablets in adult patients with schizophrenia. Secondary objective: To evaluate the safety and tolerability of cariprazine hydrochloride capsules compared with aripiprazole tablets in adult patients with schizophrenia. Exploratory objective: To explore the subjective feelings of the subjects about the treatment experience.

Start Date11 Aug 2025

Sponsor / Collaborator

Wuhan Humanwell Pharmaceutical Co., Ltd.

[+1]

CTR20251955

/ RecruitingPhase 3

在分布性休克患者中评价血管紧张素Ⅱ注射液升压治疗的有效性和安全性的多中心、随机、双盲、安慰剂对照的III期临床试验

[Translation] A multicenter, randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of angiotensin II injection in pressor therapy in patients with distributive shock

主要目的：本研究旨在证明分布性休克受试者，接受血管紧张素II注射液治疗对比安慰剂治疗能够显著提高第3小时血压有反应的受试者比例。次要目的：评价血管紧张素II注射液治疗分布性休克的安全性。

[Translation]

Primary objective: This study aimed to demonstrate that in subjects with distributive shock, angiotensin II injection treatment significantly increased the proportion of subjects with blood pressure response at 3 hours compared with placebo treatment. Secondary objective: To evaluate the safety of angiotensin II injection in the treatment of distributive shock.

Start Date25 Jul 2025

Sponsor / Collaborator

Wuhan Renfulikang Pharmaceutical Co., Ltd.

[+1]

CTR20232439

/ RecruitingPhase 2

HW021199片治疗特发性肺纤维化的多中心、随机、双盲、安慰剂对照、剂量探索IIa期临床试验

[Translation] A multicenter, randomized, double-blind, placebo-controlled, dose-finding phase IIa clinical trial of HW021199 tablets for the treatment of idiopathic pulmonary fibrosis

1、探索HW021199片治疗特发性肺纤维化的推荐剂量； 2、初步评估HW021199片治疗特发性肺纤维化的有效性和安全性； 3、评估HW021199片用于特发性肺纤维化患者的药代动力学和药效动力学特征。

[Translation]

1. Explore the recommended dose of HW021199 tablets for the treatment of idiopathic pulmonary fibrosis; 2. Preliminary evaluation of the efficacy and safety of HW021199 tablets in the treatment of idiopathic pulmonary fibrosis; 3. Evaluate the pharmacokinetic and pharmacodynamic characteristics of HW021199 tablets in patients with idiopathic pulmonary fibrosis.

Start Date25 Dec 2023

Sponsor / Collaborator

Hubei Bio-Pharmaceutical Industrial Technological Institute

[+1]

100 Clinical Results associated with Wuhan Renfulikang Pharmaceutical Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Wuhan Renfulikang Pharmaceutical Co., Ltd.

Login to view more data

100 Deals associated with Wuhan Renfulikang Pharmaceutical Co., Ltd.

Login to view more data

100 Translational Medicine associated with Wuhan Renfulikang Pharmaceutical Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 01 Oct 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 2

1

Login to view more data